Myotrophin–κB DNA interaction in the initiation process of cardiac hypertrophy  by Gupta, Sudhiranjan & Sen, Subha
Myotrophin–nB DNA interaction in the initiation process
of cardiac hypertrophy
Sudhiranjan Gupta, Subha Sen*
Department of Molecular Cardiology (NB 50), Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Received 30 October 2001; received in revised form 22 January 2002; accepted 25 January 2002
Abstract
To investigate how cardiac hypertrophy and heart failure develop, we isolated and characterized a candidate initiator, the soluble 12-kDa
protein myotrophin, from rat and human hearts. Myotrophin stimulates protein synthesis and myocardial cell growth associated with increased
levels of hypertrophy marker genes. Recombinant myotrophin from the cloned gene showed structural/functional motifs, including ankyrin
repeats and putative phosphorylation sites for protein kinase C (PKC) and casein kinase II. One repeat, homologous with I nB, interacts with
rel/NF-nB in vitro. We analyzed the interaction of recombinant myotrophin and nuclear extracts prepared from neonatal and adult
cardiomyocytes; gel mobility shift assay showed that myotrophin bound to nB DNA. To define PKC’s role in myotrophin-induced myocyte
growth, we incubated neonatal rat myocytes (normal and stretch) with specific inhibitors and found that myotrophin inhibits [3H]leucine
incorporation into myocytes and different hypertrophic gene expression in neonatal myocytes. Using confocal microscopy, we observed that a
basal level of myotrophin was present in both cytoplasm and nucleus under normal conditions, but under cyclic stretch, myotrophin levels
became elevated in the nucleus. Myotrophin gene levels were upregulated when myocytes underwent cyclic stretch or were treated with tumor
necrosis factor-a (TNF-a) or interleukin-1h and also when excised beating hearts were exposed to high pressure. Our data showed that the
myotrophin–nB interaction was increased with age in spontaneously hypertensive rats (SHRs) only. Our data provide evidence that
myotrophin–nBDNA interaction may be an important step in initiating cardiac hypertrophy.D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cardiac hypertrophy is an adaptive response of the heart to
a wide array of intrinsic stimuli, including hypertension,
myocardial infarction and cardiac arrhythmias. Because car-
diomyocytes lose the ability to divide soon after birth,
enlargement of the heart during hypertrophy involves an
increase in size and mass of individual cardiomyocytes with-
out an increase in cell number. Although initially beneficial, if
prolonged, hypertrophy can become deleterious, resulting in
dilated cardiomyopathy, heart failure and sudden death [1,2].
It is well known that cardiac hypertrophy is itself a major risk
factor associated with increased mortality. Elucidation of the
mechanism of cardiac hypertrophy is therefore important to
reduce mortality from cardiovascular causes [1,2].
Several articles have described various signal transduc-
tion pathways in cultured myocytes and transgenic mice [3].
Significant efforts have been directed toward the elucidation
of a factor involved in this process. Among the identified
factors is myotrophin, a 12-kDa soluble protein, which has
been isolated and purified from the hypertrophied hearts of
spontaneously hypertensive rat (SHR) and of humans with
dilated cardiomyopathy [4–6]. Myotrophin stimulates pro-
tein synthesis in neonatal ventricular myocytes [5] and
increases the transcript levels of immediate early proto-
oncogenes (e.g., c-myc, c-fos, and c-jun) and also genes
such as h-myosin heavy chain (MHC) and atrial natriuretic
factor (ANF), which are markers for hypertrophy [7].
Myotrophin levels become elevated in hypertensive rat
and cardiomyopathic human heart [6,8]. Increased protein
kinase C (PKC) activity has been shown in myotrophin-
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induced myocyte growth [9]. Recently, a human homolog of
myotrophin protein has been cloned, sequenced, expressed
and characterized [10]. It has been demonstrated that ele-
vated levels of myotrophin are expressed in human dilated
cardiomyopathic hearts and that recombinant human myo-
trophin produces cardiomyocyte hypertrophy [10]. All this
evidence suggests that myotrophin plays an important
signaling role in the initiation of cardiac hypertrophy. The
gene coding for myotrophin has been cloned, and the
recombinant protein has been found to be as biologically
active as native myotrophin [11]. The primary structure of
the myotrophin protein has been determined, and we have
identified significant new structural and functional motifs.
Myotrophin has an ankyrin repeat that showed some homol-
ogy with the inhibitor InBa’s ankyrin repeat. Myotrophin
also has putative phosphorylation sites for PKC and casein
kinase II [11]. Recently, we have overexpressed myotrophin
in the heart of transgenic mice and observed an invariable
progression of hypertrophy to heart failure [12].
Nuclear factor-nB (NF-nB) was originally identified as a
transcription factor bound on the enhancer element of the n-
light chain gene of B lymphocytes [13,14]. Recently, NF-nB
has been found in other cells and has been implicated in
controlling the transcription of several genes involved in
immune and inflammatory responses, cell growth and cell
adhesion, including the interleukins IL-2, IL-6, and IL-12,
tumor necrosis factor-a (TNF-a), NF-h and-m, vascular cell
adhesion molecule-1 (VCAM-1), nitric oxide synthase
(NOS), and c-myc genes. In addition, it has been demon-
strated that NF-nB activity comprises several proteins such
as p50, p65, c-rel and Rel B, with differential regulation of
their induction [15]. Although myotrophin showed rel/NF-
nB activity in vitro, the interaction of myotrophin with nB
DNA has not been determined, nor has it been established
whether this interactive phenomenon occurs in the hyper-
trophic process.
We investigated the role of the myotrophin–nB DNA
interaction in the initiation of cardiac hypertrophy. In the
present study, we evaluated this interaction in recombinant
and nuclear extracts prepared from neonatal and adult rat
cardiac myocytes. The possible involvement of PKC has
been documented in myotrophin-induced myocyte growth in
bioassay by using calphostin C and chelerythrine chloride as
two potent PKC inhibitors. We have examined the expres-
sion of three different nB-motif-containing hypertrophic
genes (c-myc, TNF-a and ANF) in myotrophin-treated neo-
natal cardiac myocytes and also in myocytes that were
treated with calphostin C prior to the treatment with myo-
trophin. We have also examined the effect of addition of
cytokines (TNF-a and IL-1h), pulsatile stretch and exposure
of an excised, beating heart to high pressure on myotrophin
gene expression. We also analyzed the pathophysiological
significance of the myotrophin–nB interaction, in which
myocytes were stretched (20%) for 6 h in an isolated heart
system, in which normal rat heart was exposed to high
pressure and in a genetic model of SHR and in which we
compared the myotrophin–nB interaction in SHRs of differ-
ent ages during progression of hypertrophy compared to
Wistar–Kyoto (WKY) rat hearts. Finally, we determined the
localization of myotrophin under cyclic stretch (to mimic
hypertension) using confocal microscopy. Our data suggest
that myotrophin interacts directly with the nB DNA site in
vitro and that this interaction is probably an important
component in the initiation process of cardiac hypertrophy.
2. Materials and methods
2.1. Materials
Timed pregnant rats were obtained from Hilltop Farms
(Scottsdale, PA). The rats were fed Purina rat chow, given
water ad libitum, and housed in AAALAC-certified facilities.
Sprague –Dawley rats weighing 250– 300 g (Harlan
Sprague–Dawley, Indianapolis, IN) were used for prepara-
tion of adult myocytes. The experimental procedures for
animals were in accordance with National Institutes of Health
guidelines. The p50 and p65 antibodies and phorbol-ester-
treated Jurkat nuclear extract (JNE) used in this study were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA), as were double-stranded NF-nB DNA (5V-AGT TGA
GGG GAC TTT CCC AGG C-3V), mutant NF-nB (same
oligonucleotide with a ‘‘G!C’’ substitution in the NF-nB
motif), OCT-1 (5V-TGT CGA ATG CAA ATC ACTAGA A-
3V) and AP-1 (5V-CGC TTG ATG ACT CAG CCG GAA-3V).
T4 polynucleotide kinase, [m32P]ATP, [a32P]CTP, [3H]leu-
cine and NAP-5 column were purchased from Amersham-
Pharmacia Biotech (Piscataway, NJ). Dulbecco’s modified
Eagle’smedium (DMEMF-12), nonessential amino acids and
antibiotic solution used for the culture of neonatal myocytes
were purchased from Life Technologies, Inc. (Rockville,
MD), as were Tris–borate ethylenediaminetetraacetic acid
(EDTA) and phosphate-buffered saline (PBS). All other
media and reagents used for preparation and culture of the
neonatal myocytes and for the preparation of adult myocytes,
including medium, fetal bovine serum albumin (BSA), insu-
lin, transferrin, fetuin, hydrocortisone and laminin were
purchased from Sigma Chemical (St. Louis, MO). Protease
inhibitors such as aprotinin, leupeptin, pepstatin andTritonX-
100 used in the preparation of nuclei isolation were also
purchased from Sigma. Collagenase was purchased from
Worthington Biochemicals (Lakewood, NJ). Heparin and
pentobarbital were purchased from Elkins-Sinn, (Cherry Hill,
NJ) and Abbott Laboratories (North Chicago, IL), respec-
tively. Calphostin C, chelerythrine chloride, recombinant
TNF-a and IL-1h were purchased from Calbiochem (La
Jolla, CA). Alexa 488 conjugated goat anti rabbit IgG and
Alexa 594 conjugated goat anti mouse IgG were purchased
from Molecular Probes, (Eugene, OR). Vectashield with
DAPI was purchased from Vector Laboratories (Burlingame,
CA). All other chemicals used in this study were molecular
biology grade and were purchased from Sigma.
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2.2. Preparation of recombinant myotrophin
Recombinant myotrophin was expressed and purified as
described previously [11]. In brief, myotrophinwas expressed
in Escherichia coli by using the T7 promoter-based vector
pET3a (Novagen, Madison, WI). Recombinant myotrophin
was expressed by growing E. coli cells in the presence of 0.1
mmol/l isopropyl thiogalactoside (IPTG) for 16 h. The soluble
recombinant myotrophin in the supernatant was separated
from the rest of the E. coli proteins by passage through
Centriprep-30 (30-kDa cut-off) followed by Centriprep-10
(10-kDa cut-off) Amicon (Bedford,MA) cartridges. The pure
recombinant myotrophin, which migrated as a single band at
the 12-kDa molecular weight region, showed biological
activity as determined by [3H]leucine incorporation into
myocyte protein and by immunoreactivity with the antibody
raised against natural myotrophin.
2.3. Antibody specificity
The specificity of antibody against myotrophin has been
described previously [7,8]. In brief, specificity of the anti-
body was established by solid phase radioimmunoassay. The
antibody did not cross-react with the known growth factors,
e.g., acidic and basic fibroblast growth factor (FGF), insulin-
like growth factor (IGH), nerve growth factor (NGF), nor-
ephinephrine (NE) and insulin. For this study, we have
checked the affinity of myotrophin antibody towards the
NF-nB proteins. Recombinant p50, c-rel protein and phor-
bol-ester-treated JNE were purchased from Santa Cruz Bio-
technology, and Western blot was done by using the
myotrophin antibody according to the standard procedure.
2.4. Preparation of cardiac myocytes
2.4.1. Neonatal myocytes
Neonatal myocytes were prepared according to the
procedure described by Sen et al. [5]. In brief, hearts from
2- to 3-day-old normal Wistar rat pups were aseptically
taken in DMEM F-12, and the ventricles were separated,
minced and incubated in DMEM F-12 containing collage-
nase (80 U/ml). Myocytes were plated on laminin-coated
wells (20 Ag/35 mm well) at a density of 106 cells/35 mm
well. On culture day 3 (or 4), myocytes were incubated in
DMEM F-12 alone and were used for the experiment as
required. BrdU was always added in the culture to prevent
the proliferation of any fibroblast contamination.
2.4.2. Adult myocytes
Adult myocytes were prepared according to the protocol
described by Sen et al. [5]. In brief, hearts removed from 17-
to 20-week-old male WKY rats were injected intraperito-
neally with heparin (100 U/100 g body weight). Fifteen
minutes later, pentobarbital sodium (5 mg/100 g body
weight) was injected. After the animal was fully anesthetized,
the heart was aseptically removed and washed with ice-cold
DMEM F-12. The aorta was cannulated and perfused with
saline. The heart was then perfused with saline containing
collagenase (200 U/ml) for the first 10 min without calcium,
and then for the next 20 min with 0.15 mM calcium. The
heart was minced and incubated in collagenase containing
phosphate buffer, and the detached cells were harvested. The
procedure was repeated four times, and the residual tissue
was found to be negligible. The viable cells were purified by
resuspending the cells in DMEM F-12, enriching them with
0.2% BSA and keeping them at 37 jC for 3 h. At the end of
incubation, viable cells had settled at the bottom, and the
supernatant was discarded. The viable cells were resus-
pended in DMEM F-12. To maintain the cells in long-term
culture, the cells were made to adhere to a laminin-coated
plate and kept in an incubator at 37 jC for 24 h.
2.4.3. Cell treatment
To study the effect of myotrophin antibody, calphostin C,
or chelerythrine chloride on myotrophin-induced stimula-
tion of protein synthesis in neonatal myocytes, we preincu-
bated the cells (on culture day 3) in DMEM F-12 containing
50 AM of each inhibitor (calphostin C and chelerythrine
chloride) in separate six-well plates. The dosage of calphos-
tin C or chelerythrine chloride was selected after many pilot
experiments using different doses of the respective inhib-
itors. The 50 AM dose showed the best inhibition without
damaging the myocytes. For myotrophin antibody, the
myocytes were incubated for 2 h (1:1000 dilution). Then,
we added myotrophin (40 nmol) and continued incubation
for 16 h. For Northern blotting, neonatal myocytes were
treated with 40 nmol myotrophin for 16–18 h, washed with
cold PBS, and harvested, and RNA was prepared. For
inhibitor studies, cells were incubated with 50 AM calphos-
tin C for 60 min and then further stimulated with 40 nmol of
myotrophin for 16–18 h. Cells were then washed with cold
PBS and harvested, and RNA was prepared.
2.4.4. Bioassay
Bioassay was done according to the procedure of Sen et
al. [5]. In brief, on culture day 3, neonatal myocytes were
incubated with either 40 nmol myotrophin or 50 AM cal-
phostin C or chelerythrine chloride in DMEM F-12 (serum
free) for 60 min. Then, we added 40 nmol myotrophin and
continued the incubation for 16 h at 37 jC. [3H]leucine (10
ACi) diluted in DMEM F-12 was added per well and
incubated for 2 h at 37 jC. The protein from each individual
well was filtered and collected using a cell harvester on
individual filter paper, and 5% trichloroacetic acid (TCA)
was used to wash the wells extensively until they were free
from radioactivity. The filter papers were air-dried for 30 min
and then counted in a beta scintillation counter after the
addition of 5 ml scintillation fluid. Data were expressed as
disintegration per minute (DPM). For stretched cells, neo-
natal myocytes, seeded in a laminin-coated FlexerCell
Stretch plate, were biaxially stretched for 6 h at 20% cell
elongation level using Flexercell Strain Unit-Model 3000.
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[3H]leucine diluted in DMEM F-12 was added per well and
was incubated as stated above. For determination of PKC
involvement in this process, cells were pretreated with 50
AM calphostin C or chelerythrine chloride in DMEM F-12
(serum free) for 60 min prior to being placed into stretch
machine for 6 h. [3H]leucine incorporation was measured as
described above.
2.5. Preparation of nuclear extracts
2.5.1. From cardiac neonatal and adult myocytes
Nuclear extract was prepared following the protocol of
Dignam et al. [16]. All buffers were kept on ice unless stated
otherwise. The protease inhibitors phenylmethylsulfonyl flu-
oride (PMSF) and dithiothreitol (DTT)were added just before
use. Cell cultures in 90-mm dishes or six-well plates were
rinsed in cold PBS, harvested by scraping, and centrifuged at
1200 g at 4 jC for 3 min. The cells were then resuspended
in buffer A (10mMHEPES/KOH, pH7.9, 1.5mMMgCl2, 10
mM KCl, 1 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 10
Ag/ml aprotinin, 1 Ag/ml leupeptin, 1 Ag/ml pepstatin and
0.5% NP-40) and incubated on ice for 10 min. The lysate was
then centrifuged at 4000 g for 4 min at 4 jC. The resulting
nuclear pellet was washed two times with buffer A without
NP-40 and resuspended in buffer B (20 mM HEPES/KOH,
pH 7.9, 25% glycerol, 420 mM NaCl, 1 mM EDTA, 1.5 mM
MgCl2, 1 mM PMSF, 0.5 mM DTT, 10 Ag/ml aprotinin, 1
Ag/ml leupeptin and 1 Ag/ml pepstatin) in a minimal volume
and was incubated on ice for 30 min with occasional vortex-
ing. After centrifugation at 15000 g for 10 min at 4 jC, the
supernatant was saved for nuclear extracts and kept in aliquots
at 70 jC. The nuclear extracts were normalized for protein
amounts determined by Bradford assay using BSA as a
standard (Bio-Rad Protein Assay Kit, Hercules, CA).
2.5.2. From rat heart
Nuclear extracts from rat heart were prepared by the
method of Costa et al. [17]. Hearts from both WKY rats
and SHRs were dissected and rinsed, minced and homogen-
ized in cold homogenization buffer (H buffer) (1 g/3 ml)
containing 0.5% Triton X-100 at 4 jC (buffer H includes 10
mM HEPES, pH 7.5, 25 mM KCl, 0.15 mM spermine, 0.5
mM spermidine, 1 mM ethyleneglycotetraacetic acid
(EGTA), 1 mM EDTA, 0.5 M sucrose, 1 mM DTT, 10 mM
benzidine hydrochloride, 1 mM PMSF, 5 Ag/ml aprotinin, 1
Ag/ml pepstatin, 1 Ag/ml leupeptin and 50 Ag/ml soybean
trypsin inhibitor). The mixture was then diluted with an equal
volume of H buffer plus Triton X-100 filtered through three
layers of cheesecloth and centrifuged at 3000 g for 10 min
at 4 jC. The nuclei were resuspended and repelleted three
times, once with Triton X-100 and twice without it. The final
pellet was suspended in H buffer without sucrose but con-
taining 2 M KCl (final concentration 0.8 M) and 25%
glycerol. The nuclear protein was extracted at 4 jC with
gentle rocking for 45 min. The lysate was centrifuged at
15000 g for 20 min at 4 jC. The supernatant was carefully
removed and was dialyzed for 4 h against a 100-fold excess of
0.1MKCl, plus 20mMHEPES (pH 7.5, plus 0.1 mMEDTA,
10% glycerol, 1 mM h-mercaptoethanol [two changes]), and
was then clarified by centrifugation at 10000 g for 20 min
at 4 jC. The final supernatant constituted the nuclear extract.
It was aliquoted and stored at 70 jC.
2.6. Electrophoretic mobility shift assay (EMSA)
EMSA was performed by using double-stranded NF-nB
DNA as a probe. The oligonucleotide of nB DNA was
purchased from Santa Cruz Biotechnology. The double-
stranded NF-nB DNA was labeled with T4 polynucleotide
kinase and [m32P]ATP and purified using a Amersham-
Pharmacia Biotechnology NAP-5 column. Ten micrograms
of nuclear protein (0.5–1 Ag in the case of recombinant
protein) was incubated in a binding buffer (10 mM Tris–
HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 40 mM NaCl, 5%
glycerol, 1 Ag/ml poly[dI–dC]) in a final volume of 20 Al on
ice for 10 min. The oligonucleotide (50000 cpm) was
added, and the reaction mixture was incubated for 20 min
at room temperature. For the supershift assay, specific
antibody was added just after ice incubation, and the
mixture was kept for another 10 min at room temperature.
For the competition studies, specific competitor (100-fold
molar excess) was added along with the binding buffer.
After incubation, DNA–protein complexes were separated
from the unbound DNA probe on a native 4% polyacryla-
mide gel in low ionic strength buffer (0.25 X TBS) by
electrophoresis at 100 V for 3 h with circulation of the
buffer. After electrophoresis, the gel was dried and exposed
to Kodak X-AR films (Kodak, NY) at 70 jC.
2.7. Preparation of beating, nonworking hearts
Beating, nonworking rat hearts were prepared according to
the method of McKee et al. [18]. In brief, 10-week-old WKY
rats were used to study the exposure of high pressure on
myotrophin mRNA levels. The rats were heparinized and
anesthetized with sodium pentobarbital. The hearts were
removed and washed with the buffer (118 mM NaCl, 4.7
mM KCl, 1.2 mM MgSO4,7H2O, 25 mM NaHCO3, 1.2 mM
KH2PO4, 0.5 mM Na-EDTA, 11 mM glucose, and 5 mM
pyruvic acid). These ingredients were dissolved in Milli-Q
water, and the buffer was bubbled with 95% O2 and 5% CO2
for 30 min. Anhydrous 2.5 mM CaCl2 was mixed in, and the
pH was adjusted to 7.35. A 95%O2 and 5% CO2 gas cylinder
was used to bubble the gas mixture continuously through the
buffer. A cylindrical water circulator connected to a 37 jC
water bath was used to keep the temperature of the circulating
buffer at 37 jC. An electrical stimulator was connected to the
atria to keep the heart beating at a constant rate. The bufferwas
kept at a certain height such that the pressure was about 135
mm Hg. In normal hearts, it was 75 mm Hg. The hearts were
kept tied with a clip and a piece of thread, and the buffer was
allowed to pass through the hearts for 2 h.
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2.8. RNA extraction and Northern blot analysis
2.8.1. From cardiac neonatal myocytes treated with
myotrophin or calphostin C
In an isolated cell system, to find out the expression of
different nB-containing hypertrophic genes, neonatal myo-
cytes were treated with 40 nmol of myotrophin for 16–18 h.
Cells were then washed with cold PBS, and total RNA was
extracted using a QIAGEN RNA Extraction kit. In another
experiment, to find out the probable role of PKC in
myotrophin-induced hypertrophic gene expression, cells
were pretreated with calphostin C for 60 min prior to the
treatment with myotrophin as described above. Yields were
quantified by absorbance at 260 nm. Experiments were
repeated with at least three different sets.
2.8.2. From beating, nonworking rat hearts
To mimic hypertension in a whole-organ system, rat
heart was exposed to high pressure as described above,
and total RNAwas extracted using the method described by
Chomczynski and Sacchi [19]. Yields were quantified by
absorbance at 260 nm. Experiments were done with at least
five different hearts on different days.
2.8.3. From isolated cardiac myocytes
In an isolated cell system, to study the effect of cyto-
kines, neonatal myocytes were treated with 30 ng/ml of
TNF-a or 10 ng/ml of IL 1-h in separate six-well plates for
1 h. After treatment, cells were washed in cold PBS, and
total RNA was extracted using a QIAGEN RNA Extraction
kit. Yields were quantified by absorbance at 260 nm.
Experiments were performed on at least five different sets.
2.8.4. From stretched cardiac myocytes
To mimic hypertension in an isolated cell system, myo-
cytes were stretched for 6 h at 20% cell elongation level
using a Flexercell unit model 3000 (Flexcell International)
in which cells were stretched in a biaxial fashion. After
stretching, cells were washed in cold PBS, and total RNA
was extracted using a QIAGEN RNA Extraction kit. Yields
were quantified by absorbance at 260 nm. Experiments were
performed on at least five different sets.
2.8.5. Northern blotting
Transcript levels of myotrophin, TNF-a, c-myc or ANF in
the above experiments were determined by Northern blot
analysis. To assess the levels of myotrophin, total RNA
samples from the experiments described were fractionated
separately on 1% agarose formaldehyde gels. A myotrophin
cDNA probe was made following the procedure described
earlier [11]. To assess the levels of TNF-a, c-myc and ANF,
RNA samples from myotrophin-treated or calphostin C-trea-
ted neonatal myocytes were fractionated as stated above.
Probes of these cDNAs were made by using a random primer
labeling kit from Roche Molecular Biochemicals (Indianap-
olis, IN). Labeled probes were purified by using a nucleotide
removal kit from QIAGEN. All hybridizations were per-
formed following the standard procedure, as suggested in the
manufacturer’s protocol. For normalization, after hybridiza-
tion with a myotrophin probe and an autoradiographic expo-
sure, the filters were stripped off and rehybridized using 18S
rRNA or GAPDH oligos as an internal loading control probe.
2.9. Western blotting and dot blotting
Total protein was isolated using M-Per Reagent (Pierce,
Rockford, IL). Western blot was done according to the
standard procedure. Proteins were electrophoretically trans-
ferred onto a PVDF membrane and probed with anti-myo-
trophin antibody at a 1:500 dilution. Protein bands were
detected using a horseradish peroxidase conjugated secon-
dary antibody and ECL (NEN). For dot blotting, protein
extracts were made from control, stretched or calphostin C-
treated neonatal myocytes using M-Per Reagent (Pierce).
Protein extracts (15 or 30 Ag) were spotted onto PVDF
membrane and probed with myotrophin antibody at a 1:500
dilution. Detection was done as described above.
2.10. Confocal microscopy
Neonatal myocytes were prepared as described above and
were plated on laminin-coated cover slips. For stretching
cells, we used membrane cells that had been stretched as
described above. Neonatal myocytes were washed with PBS
three times and were fixed with 2% paraformaldehyde for 20
min at room temperature. Cells were washed with PBS and
Fig. 1. Cross-reactivity of myotrophin antibody. Recombinant myotrophin
protein, p50 NF-nB, c-rel and JNE were separated in 10% SDS-PAGE, and
transferred onto a PVDF membrane. Western blotting was performed as
described in Materials and methods.
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were incubated with 0.1 M glycine for 5 min. After washing
with PBS, cells were permeabilized by 0.2% Triton-X-100 in
PBS for 15 min. Cells were then washed with PBS and were
blocked with 10% horse serum for 1 h at room temperature.
Cells were incubated with anti-myotrophin antibody (1:200)
overnight at 4 jC. After incubation, cells were washed in PBS
three times and were incubated with Alexa 488 conjugated
goat anti-rabbit IgG (1:1000) or Alexa 594 conjugated goat
anti-mouse IgG (1:1000, Molecular Probes) for an hour in the
dark. Cells were extensively washed with PBS and were
mounted with Vectashield containing DAPI to stain the
DNA. Confocal images were collected using a Leica TCS-
SP spectral laser scanning confocal microscope (LeicaMicro-
systems, Heidelberg, Germany) equipped with two argon ion
lasers (364 and 488 nm), as well as a krypton/argon ion laser
(568 nm). A PlanApo 20 , 0.7 oil immersion objective lens
was used. Images were exported into Adobe Photoshop for
processing and printing.
2.11. Statistical analysis
Data are presented as meanF S.D., and statistical com-
parison were made using the Student’s t-test for analysis of
variance for multiple comparisons. Significance was defined
at the P < 0.01 level.
3. Results
3.1. Specificity of myotrophin
To determine the specificity and cross-reactivity of
myotrophin antibody, Western blot analysis was performed
using NF-nB proteins (p50 and c-rel), phorbol ester-treated
JNE. Fig. 1 shows the results of Western blot analysis,
which revealed that myotrophin antibody did not cross-react
with any NF-nB proteins.
3.2. DNA binding studies
3.2.1. Specific binding of myotrophin to a nB site
EMSAswere performed with [32P]NF-nBDNA as a probe
to identify whether the nB DNA consensus was a target for
myotrophin binding. Recombinant myotrophin (500 ng) was
used in all experiments. Results are summarized in Fig. 2. A
direct binding of myotrophin to the nB consensus sequence
was observed. To confirm myotrophin’s interaction with the
Fig. 2. Effect of various factors on recombinant myotrophin binding to the
nB DNA site. Shown is an autoradiogram of an EMSA with 500 ng of
bacterially expressed recombinant myotrophin binding to [32P]NF-nB
DNA. The effect was analyzed on 4% PAGE. Competition of gel shift assay
was performed by adding a 100-fold molar excess of cold nB DNA. Cold
mutant NF-nB in 100-fold molar excess was also added in a separate
reaction to verify its real affinity to the nB site. In a separate reaction, Myo-
Ab was added and then EMSAwas performed. p50, antibody to p50 of NF-
nB; p65, antibody to p65 of NF-nB; Myo-AbG, native myotrophin-specific
antibody; OCT-1, radiolabeled Oct-1 DNA probe; AP-1, radiolabeled DNA
AP-1 probe; mNF-nB, radiolabeled mutant NF-nB DNA probe.
Fig. 3. Binding of myotrophin to nB in neonatal cardiac myocytes:
influence of various factors. (A) Myocyte nuclear extracts (MNE) were
made from neonatal rat cardiac myocytes. The autoradiogram shows results
of the gel shift assay with 10 Ag of nuclear protein binding to [32P]NF-nB
DNA; the effect was analyzed on 4% PAGE. Competition of gel shift assay
was done by adding a 100-fold molar excess of cold nB DNA Myo-Ab,
native myotrophin specific antibody. The shifted band representing the
myotrophin–nB complex is completely supershifted by the use of a
myotrophin-specific antibody. A radiolabeled mutant NF-nB failed to form
any complex. A 100-fold molar excess of cold Oct-1 or AP-1 DNA had no
effect on myotrophin binding to the nB site. (B) Myocyte nuclear extracts
(MNE) were made from adult rat cardiac myocytes. The autoradiogram
shows results of the gel shift assay with 10 Ag of nuclear protein binding to
[32P]NF-nB DNA; the effect was analyzed on 4% PAGE. Parameters used
here were the same as those mentioned in A.
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nB DNA site, EMSA was performed in the presence of
myotrophin antibody (Myo-Ab). Here, the myotrophin-
shifted nB complexes were supershifted to slowly migrating
complexes. However, reaction with p50 or p65 antibodies did
not give rise to any supershift in the in vitro binding assay. The
intensity of these complexes increased when more myotro-
phin was present in the reaction (data not shown). To confirm
its real complex formation, a 100-foldmolar excess of cold nB
Fig. 4. (A) Effect of anti-myotrophin antibody, PKC inhibitors on myotrophin-induced protein synthesis, myotrophin gene expression in neonatal rat cardiac
myocytes and stretched myocytes. Neonatal myocytes were pretreated with 50 AM of calphostin C, or chelerythrine chloride for 60 min and then treated with
myotrophin for 24 h in the presence of [3H]leucine. Cells were lysed in SDS solution, and incorporation of [3H]leucine into myocyte protein was measured as
described in the text. Data show the means (F S.E.) of five different sets of results. Myotrophin significantly stimulated [3H]leucine incorporation into myocyte
protein. Pretreatment with anti-myotrophin antibody, calphostin C or chelerythrine chloride partially blocked the stimulation. (B) Neonatal myocytes were
pretreated with 50 AM of calphostin C or chelerythrine chloride for 60 min. Cyclic stretch was applied for 6 h in the presence of [3H]leucine. Pretreatment with
calphostin C or chelerythrine chloride partially blocked the stimulation. (C) Effect of calphostin C in myotrophin-induced expression of nB-mediated
hypertrophic genes on neonatal myocytes. Samples were control myocytes and myocytes treated with myotrophin (40 nmol) for 18 h. Cells were also treated
with calphostin C for 1 h prior to the treatment with myoytrophin. Total RNA (15 Ag) was fractionated on 1% formaldehyde agarose gel and transferred to a
membrane. The membrane was then subjected to hybridization with a [a32P]dCTP-labeled TNF-a, c-myc or ANF cDNA probes separately. The blots were then
stripped off and reprobed with [m32P]dATP-labeled GAPDH oligo. (D) Samples from control and stretched myocytes treated with or without calphostin C were
fractionated on a 1% formaldehyde agarose gel and transferred to a membrane. The membrane was subjected to hybridization with a [a32P]dCTP-labeled
myotrophin cDNA probe. The blot was then stripped off and reprobed with [m32P]dATP-labeled GAPDH oligo. (E) Results from the Northern blot illustrated in
panel D were quantified by video image analyzer. An arbitrary density unit of the image analyzer was used for this purpose. Data shown are the mean (F S.E.)
of five different sets of experiments (meanF S.E.). (F) Protein samples (15 and 30 Ag) from control and stretched myocytes treated with or without calphostin
C were spotted onto PVDF membrane and hybridized with myotrophin antibody as described in Materials and methods.
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DNAwas used as a competitor, and it completely abolished
the binding. Cold OCT-1 did not affect the binding of
myotrophin to nB. When an unrelated probe (OCT-1 or AP-
1) was used, myotrophin did not form any complexes with
them, which further shows its affinity toward the nB DNA
sites. A mutant probe of NF-nB DNA also did not show any
binding to myotrophin. A 100-fold molar excess of cold
mutant NF-nB did not affect the binding of myotrophin to
nB. Finally, to verify any contamination or cross-reactivity of
myotrophin antibody to nBDNA consensus, EMSAwas also
performed using myotrophin antibody as a substrate. It is
observed that myo-Ab did not form any complex with nB
DNA. All these data suggest that recombinant myotrophin
directly binds to nB sites (Fig. 2).
3.2.2. Interaction of the jb site with nuclear extract derived
from neonatal and adult rat cardiac myocytes
EMSA was performed by using 10 Ag of nuclear protein
from neonatal and adult rat cardiac myocytes. In both cases,
we observed that myotrophin bound to the nB site. The
myotrophin–nB complex was completely abolished by the
addition of a 100-fold molar excess of cold nB DNA in the
reaction mixture. Myotrophin antibody was used in each
reaction, and nB complexes were supershifted to more
slowly migrating complexes. A mutant nB DNA also did
not show any binding to myotrophin. Again, cold OCT-1,
AP-1 or mutant nB DNA did not affect the binding of
myotrophin to nB DNA (Fig 3A,B).
3.3. Involvement of PKC in myotrophin-induced signaling
cascade
3.3.1. Effect of calphostin C, chelerythrine chloride,
myotrophin antibody on myotrophin-induced or stretch-
induced protein synthesis in neonatal rat myocytes
To explore how PKC is involved in the signaling cascade,
we performed our bioassay (measuring the incorporation of
[3H]leucine into the myocyte protein) by incubating the
neonatal rat myocytes with calphostin C or chelerythrine
chloride (Fig 4A). To assess the involvement of PKC in
cyclic stretch, neonatal myocytes were incubated with the
same inhibitors as stated above prior to application of stretch
and measured [3H]leucine incorporation into myocyte pro-
tein (Fig. 4B). An inhibition of [3H]leucine incorporation
Fig. 5. Localization of myotrophin protein by confocal microscopy. Confocal microscopy was performed as described in Materials and methods. (A) Control
neonatal myocytes were stained with myotrophin antibody and detected with Alexa 488 goat anti-rabbit IgG. (B) Corresponding field stained with DAPI. (C)
Neonatal myocytes on laminin-coated membrane were stained with myotrophin antibody and detected with Alexa 488 goat anti-rabbit IgG. (D) Corresponding
field stained with DAPI. (E) Neonatal myocytes treated with calphostin C prior to the 6-h 20% pulsatile stretch. (F) Corresponding field stained with DAPI.
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into the myocyte protein was observed in both cases, which
suggests that PKC is involved in the signaling cascade.
To analyze further the involvement of PKC in the
myotrophin-induced signaling cascade, we evaluated the
expression level of three different hypertrophic marker
genes expression in neonatal myocytes treated with myo-
trophin or calphostin C prior to the treatment with myo-
trophin and performed Northern blot analysis using c-myc
(kindly provided by Dr. A. Larner, Department of Immu-
nology, Cleveland Clinic Foundation, Cleveland, OH),
TNF-a (kindly provided by Dr. A.M. Feldman, ATCC No.
63169) and ANF cDNA as a probe. The result is shown in
Fig. 4C. A partial inhibition in the transcript levels of all
three genes were found when they were treated with
calphostin C, suggesting a role of PKC in myotrophin-
induced expression of the above genes.
To find out the expression level of myotrophin under
cyclic stretch and also the involvement of PKC in this
cascade, we incubated the cells with calphostin C prior to
application of biaxial cyclic stretch. We analyzed the myo-
trophin mRNA expression level and protein level; the results
are summarized in Fig. 4D–F. Myotrophin gene levels were
upregulated when the myocytes underwent cyclic stretch and
were partially inhibited when myocytes were treated with
calphostin C, suggesting a role of PKC in this signaling
cascade (Fig. 4D). Quantification of Fig. 4D is shown in Fig.
4E. The figure is representative of five different sets and the
data are expressed in percent over control. Statistical compar-
isons weremade using Student’s t-test for analysis of variance
and was defined at P < 0.01 level. We observed that myo-
trophin gene expression was elevated to 86% (over control) in
cyclic stretch-induced cells and was diminished to 23% (over
control) when the cells were treated with calphostin C.
Finally, we measured the myotrophin protein level in
stretch-induced and calphostin C-treated neonatal myocytes
by dot blotting. For quantification, we measured the expres-
sion levels of myotrophin protein with varied amounts (15
and 30 Ag) from control, stretched and calphostin C-treated
cells. The results are summarized in Fig. 4F. Our data
showed a partial inhibition of myotrophin protein for cells
treated with calphostin C. All these data suggest that the
myotrophin-induced hypertrophic process is partly mediated
through PKC and probably an important step in the initia-
tion process of cardiac hypertrophy.
3.3.2. Location of myotrophin in the neonatal myocytes
To localize myotrophin protein in the cell, confocal micro-
scopy was done. In the normal neonatal myocytes, myotro-
phin was found in the cytoplasm and nucleus (as evident by
the green fluorescence in both). Although not all nuclei are
loaded with myotrophin under normal conditions (Fig. 5A),
DNAwas stained by DAPI as shown in Fig. 5B. However, in
the stretched cells, more nuclei were found to be loaded with
myotrophin at 6 h of 20% pulsatile stretch as compared to the
control cells (Fig. 5C). Here also, DNAwas stained by DAPI
(Fig 5D). Fig 5E shows the calphostin C-treated cells. Here,
we found that fewer nuclei were loaded with myotrophin
compared with those of the stretched cells (Fig. 5C). The field
corresponding to Fig. 5E was stained with DAPI (Fig. 5F).
Fig. 6. Northern blot hybridization analysis of myotrophin mRNA
expression: (A) In neonatal cardiac myocytes treated with TNFa and IL-
1h. Samples were control myocytes and myocytes treated with 30 ng/ml
TNFa and 10 ng/ml IL-1h. Total RNA was isolated from myocytes
separately. Total RNA (15 Ag) was fractionated on 1% formaldehyde
agarose gel and transferred to a membrane. The membrane was then
subjected to hybridization with a [a32P]dCTP-labeled myotrophin cDNA
probe. The blot was then stripped off and reprobed with [m32P]dATP-
labeled 18S rRNA. Results from the Northern blot illustrated in panel A
were quantified by video image analyzer. An arbitrary density unit of the
image analyzer (B) was used for this purpose. Data shown are the mean of
five different sets of experiments (meanF S.E.). (C) In beating, non-
working rat hearts exposed to high pressure. Samples of normal rat heart
and heart subjected to high pressure (135 mm Hg) for 2 h in a beating
condition were tested. Total RNA was isolated from rat hearts separately.
Total RNA (20 Ag) was fractionated on a 1% formaldehyde agarose gel and
transferred to a membrane. The membrane was then subjected to
hybridization with a [a32P]dCTP-labeled myotrophin cDNA probe. The
blot was stripped off and reprobed with [m32P]dATP-labeled 18 S rRNA
probe. Results from the Northern blot illustrated in panel (D) were
quantified by video image analyzer. An arbitrary density unit of the image
analyzer was used for this purpose. Data shown are the means (F S.E.) of
three different sets of experiments.
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3.4. Effect of various hypertrophic stimuli in myotrophin
gene expression
3.4.1. Effect of cytokines on myotrophin gene expression
The effects of TNF-a and IL-1h on myotrophin gene
expression are shown in Fig. 6A. A significant upregulation
of myotrophin gene was observed by both treatment with
TNF-a and IL-1h. The left panel (Fig. 6A) shows the
Northern blot analysis of myotrophin gene expression in
TNF-a- and IL-1h-treated cardiac myocytes. The right
panel (Fig. 6B) showed the quantification of the autorads
in five different sets. Data are expressed in percent over
control. Statistical comparisons were made using Student’s
t-test for analysis of variance and was defined at the P < 0.01
level. We observed that myotrophin gene expression was
elevated to 97% (over control) in TNF-a-treated cells and
72% (over control) in IL-1h-treated cells.
3.4.2. Effect of exposure of heart to high pressure on
myotrophin gene expression
To mimic the effect on hypertension in an isolated heart
system, normal hearts were exposed to high pressure (135
mm Hg), other hearts were kept at 75 mm Hg as controls.
Northern blotting was done with myotrophin cDNA as a
probe, and the result is shown in Fig. 6C. A significant
increase in myotrophin gene was observed when the heart
exposed to high pressure. The left panel (Fig. 6C) shows the
Northern blot analysis of myotrophin gene expression in the
normal rat heart exposed to high pressure. The right panel
(Fig. 6D) shows the quantification of the autorads in three
different sets. Data are expressed in percent over control.
Statistical comparisons were made using Student’s t-test for
analysis of variance and was defined at the P < 0.01 level.
We observed that myotrophin gene expression was elevated
to 78% (over control) in the hearts exposed to high pressure.
3.5. Pathophysiological studies
3.5.1. Interaction of myotrophin to nb DNA with nuclear
extracts prepared from SHR and WKY rat hearts
To evaluate the interaction of myotrophin to nB DNA in
two different age groups of SHR hearts and the normal rat
hearts (WKY), nuclear extracts were prepared from the hearts
of 6- and 17-week-old SHR and WKY rats. In each reaction,
Fig. 7. EMSAwith a site-specific probe and nuclear protein isolated from WKY and SHR rats at 6- and 17-week of ages. (A) [32P]NF-nB DNAwas used as a
probe in all the reactions. Nuclear protein (10 Ag) was used in all lanes. Competition of gel shift assay was performed by adding a 100-fold molar excess of cold
NF-nB DNA. The complex representing myotrophin–nB is supershifted by the use of Myo-Ab, a myotrophin specific antibody. (B) Quantification of
myotrophin–NF-nB binding in normal WKY rats and SHR using 10 Ag nuclear protein from each type of heart tissue. Results from the gel mobility shift assay
illustrated in panel A were quantified by video image analyzer. An arbitrary density unit of the image analyzer was used for this purpose. Data shown are the
means (F S.E.) of three different sets of experiments.
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10 Ag protein was incubated with [32P]NF-nB DNA, and
EMSAwas performed. The data are summarized in Fig. 7A.
A significant increase in the binding of myotrophin to nB
DNA was observed in both SHR age groups. Furthermore,
among SHRs, binding efficiency of myotrophin to nB was
increased from 6 to 17 weeks, whereas in WKY rats, binding
efficiencies remain unchanged (Fig. 7A). The specificity of
binding was confirmed by supershift assay with myotrophin
antibody and also by adding cold competitor. Quantification
of Fig. 7A is shown in Fig. 7B. Data are presented in three
different sets and are expressed in an arbitrary unit of density
per 10 Ag of protein. Statistical comparisons were made using
Student’s t-test for analysis of variance and was defined at the
P < 0.01 level. We observed that the myotrophin–nB DNA
interaction was increased at 17 weeks SHR in comparison to
6-week-old SHRs; within WKY, there was no significant
variation.
3.5.2. Effect of biaxial cyclic stretch on myotrophin–jb
DNA interaction in neonatal rat myocytes
To compare the myotrophin–nB interaction in control
myocytes with that of myocytes subjected to biaxial cyclic
stretch for 6 h at 20% cell elongation level, we prepared the
nuclear extracts from the above samples, and EMSA was
performed using [32P]NF-nB DNA as a probe. The result is
shown in Fig. 8A. We observed that compared with con-
trols, an enhanced binding of myotrophin to nB occurred
when the cells underwent cyclic stretch. The formation of
the myotrophin–nB complex was confirmed by supershift
analysis using myotrophin antibody and also by cold com-
petition assay using 100-fold molar excess cold nB DNA.
3.5.3. Effect of exposure to high pressure on myotrophin–
jb interaction
To compare the myotrophin–nB DNA interaction in
hypertensive condition, normal rat heart was exposed to
high pressure (135 mm Hg) and EMSA was performed
using [32P]NF-nB DNA as a probe. The result is shown in
Fig. 8B. We observed that compared with controls, the
binding of myotrophin to nB DNA was significantly
increased when the heart is exposed to high pressure.
Formation of the myotrophin–nB complex was confirmed
by supershift analysis as well as by cold competition assay.
4. Discussion
Cardiac myotrophin is a soluble 12-kDa protein, previ-
ously isolated and purified from hypertrophied SHR heart
[5] and human cardiomyopathic heart [6]. The gene coding
for myotrophin has been cloned, sequenced, characterized
and expressed in E. coli [11]. Myotrophin is identical to the
functionally undefined protein V1, which has been isolated
from rat brain. It is now evident that V1 (myotrophin) falls
under the cdc10/SW16 motif, which contains a protein
superfamily that may play a role in intracellular signaling
[20,21].
The molecular mechanism by which myotrophin stimu-
lates cardiomyocyte hypertrophy is not known, but the
interaction may be with nB transcription factors. We previ-
ously reported that cardiac myotrophin exhibits rel/NF-nB
interacting activity in vitro [11], possibly via its internal
ankyrin repeat motif. Ankyrin repeats (generally 33 amino
acids long) are protein-interacting domains that possess both a
highly conserved and a highly variable region; the latter most
likely confers specificity to a given protein. Other proteins
have been reported to contain this motif, but they are hetero-
geneous in nature and demonstrate varied distribution and
subcellular localization as well as diverse function [22]. The
homology between ankyrin repeat #2 of rat myotrophin and
the repeats of InBa may have functional significance [11].
Fig. 8. Binding of myotrophin to nB: influence of biaxial pulsatile stretch
and high pressure. (A) Nuclear extracts (NE) were made from control
myocytes, and the myocytes were subjected to stretch at 20% cell
elongation level. Results from this autoradiogram show the gel shift assay
with 10 Ag nuclear protein binding to [32P]NF-nB DNA; the effect was
analyzed on 4% PAGE. Complex formation was checked by supershift
analysis as well as competition assay. Experiments were repeated five times
on different days. (B) Nuclear extracts (NE) were made from normal rat
heart and heart subjected to high pressure (135 mm Hg). Results from this
autoradiogram show the gel shift assay with 10 Ag nuclear protein binding
to [32P]NF-nB DNA; the effect was analyzed on 4% PAGE. Complex
formation was checked as described in panel A. Experiments were repeated
three times on different days.
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The primary structure of myotrophin reveals the presence of
putative phosphorylation sites for PKC and casein kinase II,
which are also observed in InBa proteins.We first determined
the cross-reactivity of myotrophin antibody by using phorbol
ester-treated JNE, recombinant p50 and c-rel proteins and
observed that myotrophin did not cross-react with them (Fig.
1). In this study, we demonstrated the functional significance
of these homologies by gel shift assays. Our data show that
recombinant myotrophin and the nuclear extracts prepared
from myocytes can bind with nB DNA in gel mobility shift
assays. Antibody raised against myotrophin also showed a
supershift in the same binding assay (Figs. 2 and 3). In
contrast, no supershift was observed when p50 or p65 anti-
bodies were used in EMSA. A 100-fold molar excess of cold
nB DNA completely abolished the binding, demonstrating
myotrophin’s real specificity toward nB DNA. Mutant nB,
AP-1 and OCT-1 DNA failed to form a complex with
myotrophin, a fact that provides additional proof for myo-
trophin’s affinity to nB DNA. Apart from the gel mobility
shift assay, we have also observed a direct binding of
myotrophin to nB DNA by South–Western blotting (data
not shown). Taken together, all these data indicate that
myotrophin interacts directly with nB DNA in vitro. In our
previous results [11], based on the gel mobility shift assay, no
DNA–protein interaction was apparent. In the present study,
we showed myotrophin’s direct binding to nB DNA, and
rigorous efforts using a number of techniques prove that this
finding is valid.
It is widely appreciated that NF-nB is a ubiquitously
expressed transcription factor involved in the activation of
genes associated with inflammation, lymphoid differentia-
tion, embryonic axis determination, cell adhesion, viral gene
transcription and cell proliferation [23]. It is well established
that the rel/NF-nB proteins are subject to multiple regula-
tory influences. A major aspect of this regulation is the
control of intracellular localization of these proteins, with
inactive protein maintained in the cytoplasm and transcrip-
tionally active protein transported to the nucleus. The
cytoplasmic retention of the inactive forms of rel/NF-nB
is achieved through interaction with a group of inhibitory
molecules called InBs [24,25]. The activation of NF-nB has
been documented in various signaling cascades that include
TNF-a-treated vascular smooth muscle cell proliferation, in
the late phase of ischemic preconditioning in conscious
rabbits and in some patients with congestive heart failure
[26–29]. However, there is no direct evidence of nB-
mediated gene expression in the cardiac hypertrophic proc-
ess. The present study focused on finding whether myotro-
phin induces expression of various hypertrophic genes that
contain a nB DNA motif in their 5V upstream region and on
the probable involvement of PKC in this process.
Our data demonstrates that myotrophin- or stretch-
induced [3H]leucine incorporation into myocyte protein
was inhibited by pretreatment of cells with calphostin C or
chelerythrine chloride (Fig. 4A,B), suggesting the involve-
ment of PKC in this process. Other studies also suggest an
important role for PKC, as an intracellular mediator for the
effect of some hypertrophic growth stimuli [30–32]. PKC
may also be a candidate second messenger in the neuro-
humoral induction of myocardial hypertrophy. It has been
demonstrated that overexpression of the PKC h2 isoform in
myocardium resulted in cardiac hypertrophy [33].
To determine if PKC is involved in the nB-mediated
expression of other hypertrophic genes, we took two
approaches. We first analyzed different hypertrophic marker
genes, including TNF-a, c-myc and ANF, in neonatal
myocytes. All these genes are known to contain a nB-like
motif in their 5V upstream region [34–40]. It has been
reported by many investigators that ANF, TNF-a and c-
myc actively participate in the hypertrophic process [41–
49]. In our transgenic model, in which myotrophin is over-
expressed in the mouse heart, we have also found a high
level of expression of these genes [12]. In the present study,
we analyzed the expression of these genes in myotrophin-
treated neonatal myocytes and found them to be upregulated
(Fig. 4C). To determine whether the expression of these
genes is mediated through PKC, we incubated the myocytes
with calphostin C and observed that the expression of these
genes is partially inhibited, suggesting a specific role of
PKC in the myotrophin-induced signaling cascade (Fig.
4C). In the second approach, because we considered myo-
trophin a good candidate for involvement in cardiac hyper-
trophy, we incubated the myocytes with the PKC inhibitor
calphostin C, then subjected them to cyclic stretch for 6 h.
Our data showed a significant inhibition of the transcript
level of the myotrophin gene (Fig. 4D,E). These data
prompted us to quantify the myotrophin protein in calphos-
tin C-treated myocytes prior to subjecting them to cyclic
stretch. A significant inhibition was also observed in cal-
phostin C-treated cells in comparison to the stretched cells
(Fig. 4F). Taken together, all these data demonstrate that
PKC-dependent signaling pathways probably function in the
myotrophin-induced initiation of cardiac hypertrophy.
Several reports over the past few years have shown that
TNF-a induces a hypertrophic growth response in cardiac
myocytes and may play an important role in myocardial
homeostasis after environmental stress [50,51]. Recently, it
has also been shown that IL-1h is one of the important
factors that causes cardiac hypertrophy in heart failure and
acute myocardial infarction [52]. Francis et al. [53] have
shown that local production of IL-1h occurs in the coronary
arteries and myocardium of patients with dilated cardiomy-
opathy. In this study, we have used both TNF-a and IL-1h
to investigate myotrophin gene expression and have
observed an upregulation of the myotrophin gene (Fig. 6A).
In an isolated cell system, Sadoshima et al [54] have
shown that the phenotype of mechanically stretched cardi-
omyocytes closely mimics that of hemodynamic load-
induced hypertrophy in vivo. This system may be a suitable
experimental model to study how mechanical load is trans-
lated into intracellular signals regulating gene expression.
To evaluate the myotrophin gene, we used a computerized
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cyclic stretch method by which a biaxial pulsatile stretch
was applied to cardiac neonatal myocytes. We observed an
upregulation of myotrophin gene expression after stretching
neonatal myocytes for 6 h applying 20% stretch (Fig. 4D,E).
To evaluate the effect of high pressure onmyotrophin gene
expression, we used a beating, nonworking heart preparation,
in which rat hearts were exposed to high pressure. We
observed that high pressure significantly increased transcript
levels of the myotrophin gene from the same heart exposed to
normal pressure (75 mm Hg) (Fig. 6B).
To evaluate the myotrophin–nB DNA interaction in a
genetic model of hypertensive hypertrophy, we compared
the binding efficiency of SHRs and age- and sex-matched
normal WKY rats. With advancement of hypertrophy in
SHRs, a significant increase in myotrophin–nB binding was
observed at 6 weeks of age compared to age- and sex-
matched WKY controls (Fig. 7A,B). At this age, in SHRs, a
significant increase in myotrophin was reported previously
[6,8]. In WKY rats, on the other hand, the binding efficien-
cies of nB DNA and myotrophin protein remained
unchanged between 6 and 17 weeks of age. In our previous
report, we showed that in SHRs, the myotrophin level
remains high [6,8]. However, at that point, we had not yet
observed evidence of direct myotrophin–nB binding. After
numerous experiments since then, we have gathered strong
and varied data suggesting that the enhanced binding is due
to an increased level of myotrophin present in the hearts. We
have also compared the myotrophin–nB interaction in an
isolated cell system by imposing biaxial pulsatile stretch and
in an isolated heart system by exposing the heart to high
pressure. Both experiments mimicked the in vivo hyper-
tensive condition. We observed that the myotrophin–nB
DNA interaction was accelerated in both cases (Fig. 8). This
enhanced binding of myotrophin to nB DNA may be due to
the synthesis of more myotrophin under hypertensive con-
ditions or to translocation of myotrophin from the cytoplasm
to the nucleus. Confocal microscopic data showed the
presence of myotrophin in both cytoplasm and nucleus of
normal neonatal myocytes. However, an elevated level of
myotrophin was observed in the nucleus after 6 h (20%) of
biaxial cyclic stretch (Fig. 5C,E). The level of myotrophin
protein decreased when the cells were pretreated with
calphostin C prior to applying stretch (Fig. 5G). These data
further suggest that myotrophin may play a role in the
growth-promoting activity of the myocytes.
We have demonstrated three important observations
elucidating the mechanism of action of hypertrophy. First,
we have shown convincingly that myotrophin interacts
directly with nB DNA in vitro. Secondly, we have shown
that myotrophin induced different nB-containing hypertro-
phic gene expression as well as increased protein synthesis
was mediated through PKC in neonatal myocytes. We have
also shown that upregulation of the myotrophin gene occurs
under hypertensive conditions, e.g., high pressure and cyclic
stretch and after treatment with cytokines (TNF-a and IL-
1h). Finally, we have shown that the myotrophin–nB DNA
interaction was increased under different hypertensive con-
ditions and also in the older age group of SHR hearts. Our
data suggest that probably myotrophin acts as a transcription
factor by using nB DNA as a target for its activation. To the
best of our knowledge, this is the first report demonstrating
the interaction of myotrophin with nB, which appears to be
an important step in the signal transduction pathway for the
initiation of cardiac hypertrophy.
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